Blockade of nicotinic acetylcholine receptor enhances the responsiveness to bupropion in the mouse forced swim test
Sign Up to like & getrecommendations! Published in 2019 at "Behavioural Brain Research"
DOI: 10.1016/j.bbr.2018.12.027
Abstract: HIGHLIGHTSRole of nicotinic receptors was tested in the antidepressant effects of bupropion.&agr;4, &agr;5, &agr;6, and &bgr;2 nicotinic receptor subunit WT&KO mice were studied using the FST.&agr;4, &agr;6, and &bgr;2 subunits modulate the antidepressant‐like effects of… read more here.
Keywords: agr bgr; agr; mice; agr agr ... See more keywords
Assessment of individual differences in response to acute bupropion or varenicline treatment using a long-access nicotine self-administration model and behavioral economics in female rats
Sign Up to like & getrecommendations! Published in 2020 at "Behavioural Brain Research"
DOI: 10.1016/j.bbr.2020.112558
Abstract: Bupropion and varenicline are widely prescribed pharmacological treatments for smoking cessation. These treatments are only marginally effective in clinical populations but most preclinical studies show that they are effective in decreasing self-administration in rats on… read more here.
Keywords: nicotine; bupropion varenicline; bupropion; access ... See more keywords
In vitro to in vivo extrapolation of the complex drug‐drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical Pharmacology"
DOI: 10.1016/j.bcp.2016.11.007
Abstract: Graphical abstract Figure. No Caption available. Abstract Bupropion is a widely used antidepressant and smoking cessation aid and a strong inhibitor of CYP2D6 in vivo. Bupropion is administered as a racemic mixture of R‐ and… read more here.
Keywords: cyp2d6; drug; bupropion metabolites; reversible inhibition ... See more keywords
Bupropion for postpartum smoking relapse: A remote protocol for a two-arm, double-blind, placebo-controlled randomized clinical trial.
Sign Up to like & getrecommendations! Published in 2021 at "Contemporary clinical trials"
DOI: 10.1016/j.cct.2021.106352
Abstract: Cigarette smoking among postpartum women remains a significant public health problem despite known health risks to women and their newborns. It is estimated that over 50% of women quit smoking during pregnancy but 90% relapse… read more here.
Keywords: trial; smoking relapse; relapse; postpartum ... See more keywords
Bupropion induced hyponatremia: A review of literature
Sign Up to like & getrecommendations! Published in 2017 at "European Psychiatry"
DOI: 10.1016/j.eurpsy.2017.01.1391
Abstract: Introduction For over 20 years, bupropion has been used as an antidepressant by inhibiting the norepinephrine-dopamine reuptake. Hyponatremia is a relatively rare condition that has been associated with the use of antidepressants including selective serotonin… read more here.
Keywords: literature; induced hyponatremia; hyponatremia; bupropion induced ... See more keywords
Evidence of hypoglycemic anhedonia and modulation by bupropion in rats
Sign Up to like & getrecommendations! Published in 2021 at "Pharmacology Biochemistry and Behavior"
DOI: 10.1016/j.pbb.2021.173120
Abstract: BACKGROUND Disorders characterized by dysfunction of glucose metabolism are often comorbid with depression. The current study investigated whether a hypoglycemic state caused by 2-deoxy-D-glucose (2-DG) can result in anhedonic behaviors responsive to stimulation of monoamine… read more here.
Keywords: anhedonia modulation; evidence hypoglycemic; hypoglycemic anhedonia; taste reactivity ... See more keywords
Are all antidepressants the same? The consumer has a point.
Sign Up to like & getrecommendations! Published in 2022 at "Psychological medicine"
DOI: 10.1017/s0033291722000678
Abstract: BACKGROUND Although a large variety of antidepressants agents (AD) with different mechanisms of action are available, no significant differences in efficacy and safety have been shown. However, there have been few attempts to incorporate data… read more here.
Keywords: medicine; emotional blunting; consumer point; treatment ... See more keywords
Mechanistic Approach for Toxic Effects of Bupropion in Primary Rat Hepatocytes.
Sign Up to like & getrecommendations! Published in 2017 at "Drug research"
DOI: 10.1055/s-0042-123034
Abstract: Bupropion is a widely prescribed antidepressant/smoke cessation drug. However, hepatotoxicity is one of its side effects reported in some recipients. The mechanisms by which bupropion induces hepatotoxicity is not clear yet. This experiment was intended… read more here.
Keywords: rat hepatocytes; alpha tos; bupropion; mechanistic approach ... See more keywords
Practice patterns of bupropion co-prescription with antipsychotic medications
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Addictive Diseases"
DOI: 10.1080/10550887.2022.2028531
Abstract: Abstract Objective: Bupropion is one of the few medications with an FDA indication for smoking cessation. This is of particular significance due to the high co-morbidity of tobacco use disorder in patients with schizophrenia spectrum… read more here.
Keywords: antipsychotic medications; practice patterns; bupropion antipsychotic; patterns bupropion ... See more keywords
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials
Sign Up to like & getrecommendations! Published in 2021 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2021.1898588
Abstract: ABSTRACT Introduction The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-based antidepressants invites the need for mechanistically novel treatments. Convergent evidence implicates glutamatergic signaling as a potential therapeutic… read more here.
Keywords: depression; mdd; treatment; dxm bupropion ... See more keywords
Is there a therapeutic potential in combining bupropion and naltrexone in schizophrenia?
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Neurotherapeutics"
DOI: 10.1080/14737175.2022.2124369
Abstract: ABSTRACT Introduction A sustained-release tablet composed of a combination of the dopamine and norepinephrine reuptake inhibitor bupropion (BUP) and the µ-opioid receptor antagonist naltrexone (NAT) is marketed under the brand name Contrave by Orexigen Therapeutics… read more here.
Keywords: potential combining; bupropion naltrexone; therapeutic potential; schizophrenia ... See more keywords